JP2019511236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511236A5 JP2019511236A5 JP2018554069A JP2018554069A JP2019511236A5 JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5 JP 2018554069 A JP2018554069 A JP 2018554069A JP 2018554069 A JP2018554069 A JP 2018554069A JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- nucleic acid
- site
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 57
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 56
- 150000007523 nucleic acids Chemical group 0.000 claims description 37
- 108091008874 T cell receptors Proteins 0.000 claims description 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 230000010354 integration Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000006801 homologous recombination Effects 0.000 claims description 6
- 238000002744 homologous recombination Methods 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 4
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 14
- 239000003937 drug carrier Substances 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 210000002378 Th9 Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323623P | 2016-04-15 | 2016-04-15 | |
| US62/323,623 | 2016-04-15 | ||
| US201662323675P | 2016-04-16 | 2016-04-16 | |
| US62/323,675 | 2016-04-16 | ||
| US201762461677P | 2017-02-21 | 2017-02-21 | |
| US62/461,677 | 2017-02-21 | ||
| US201762462243P | 2017-02-22 | 2017-02-22 | |
| US62/462,243 | 2017-02-22 | ||
| PCT/US2017/027601 WO2017180989A2 (en) | 2016-04-15 | 2017-04-14 | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511236A JP2019511236A (ja) | 2019-04-25 |
| JP2019511236A5 true JP2019511236A5 (enExample) | 2020-05-28 |
| JP7058223B2 JP7058223B2 (ja) | 2022-04-21 |
Family
ID=59285314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554069A Active JP7058223B2 (ja) | 2016-04-15 | 2017-04-14 | トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377637B2 (enExample) |
| EP (3) | EP4628587A2 (enExample) |
| JP (1) | JP7058223B2 (enExample) |
| KR (3) | KR20240000616A (enExample) |
| CN (1) | CN109790517B (enExample) |
| AU (1) | AU2017250769B2 (enExample) |
| BR (1) | BR112018071199A2 (enExample) |
| ES (2) | ES2933961T3 (enExample) |
| PT (2) | PT3443075T (enExample) |
| SG (1) | SG11201808831TA (enExample) |
| WO (1) | WO2017180989A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6800859B2 (ja) | 2015-01-26 | 2020-12-16 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| JP2018518181A (ja) * | 2015-06-17 | 2018-07-12 | ザ ユーエービー リサーチ ファンデーション | 血液細胞系列の細胞に機能的ポリペプチドを導入するためのＣＲＩＳＰＲ／Ｃａｓ９複合体 |
| CN107949641A (zh) | 2015-06-17 | 2018-04-20 | Uab研究基金会 | 用于基因组编辑的crispr/cas9复合物 |
| CN108601821B (zh) * | 2015-10-05 | 2023-09-19 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| ES2883116T3 (es) | 2015-10-05 | 2021-12-07 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| CN115806940A (zh) * | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| JP7534070B2 (ja) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| JP2019510503A (ja) * | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| AU2017250769B2 (en) | 2016-04-15 | 2022-07-14 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| MX2019004215A (es) * | 2016-10-19 | 2019-08-21 | Cellectis | Insercion de genes dirigida para terapia de celulas inmunes mejorada. |
| WO2018081476A2 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| EP3618870A4 (en) | 2017-05-01 | 2021-04-21 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES |
| CA3067382A1 (en) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Targeted non-viral dna insertions |
| EP3645038A1 (en) | 2017-06-30 | 2020-05-06 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| US20200216515A1 (en) * | 2017-07-26 | 2020-07-09 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection |
| IL305485B2 (en) * | 2017-10-27 | 2025-10-01 | Univ California | Targeted replacement of endogenous T cell receptors |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| KR102828999B1 (ko) * | 2018-02-11 | 2025-07-04 | 메모리얼 슬로안 케터링 캔서 센터 | 비-hla 제한된 t 세포 수용체 및 이의 용도 |
| WO2019161271A1 (en) * | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| US20210032661A1 (en) * | 2018-04-09 | 2021-02-04 | The Trustees Of The University Of Pennsylvania | Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An Effector |
| AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
| WO2019204397A1 (en) * | 2018-04-17 | 2019-10-24 | Wake Forest University Health Sciences | Methods and compositions for th9 cell mediated cancer treatment |
| US20210207174A1 (en) * | 2018-05-25 | 2021-07-08 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| JP2021525530A (ja) * | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| TW202015719A (zh) | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| JP2021529559A (ja) * | 2018-07-03 | 2021-11-04 | ソティオ，リミティド ライアビリティ カンパニー | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
| JP7422365B2 (ja) * | 2018-07-26 | 2024-01-26 | 国立大学法人京都大学 | 外来抗原レセプター遺伝子導入細胞の製造方法 |
| IL280322B2 (en) | 2018-08-14 | 2025-06-01 | Sotio Llc | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| MX2021006968A (es) | 2018-12-12 | 2021-10-13 | Kite Pharma Inc | Antígeno quimérico y receptores de las células t, y métodos de uso. |
| US20220016171A1 (en) * | 2018-12-18 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| CN113874027A (zh) * | 2019-02-01 | 2021-12-31 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| WO2020172177A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| CN119932065A (zh) * | 2019-03-06 | 2025-05-06 | 莱蒂恩技术公司 | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 |
| KR20210134932A (ko) | 2019-03-29 | 2021-11-11 | 에프. 호프만-라 로슈 아게 | 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 FcRn 발현 세포를 생성하는 방법 |
| BR112021019772A2 (pt) * | 2019-04-11 | 2022-01-04 | Fate Therapeutics Inc | Reconstituição de cd3 em células efetoras imunes e ipsc geneticamente modificadas |
| BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
| CA3140064A1 (en) * | 2019-05-16 | 2020-11-19 | University Of Washington | Lockr-mediated recruitment of car t cells |
| EP3986925A1 (en) * | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| EP3999079A4 (en) | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN117925528A (zh) * | 2019-07-24 | 2024-04-26 | 浙江煦顼技术有限公司 | 具有增强记忆t细胞表型的修饰t细胞 |
| CA3151690A1 (en) * | 2019-09-23 | 2021-04-01 | Beau WEBBER | Genetically-edited immune cells and methods of therapy |
| WO2021061946A2 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | A promoter specific for non-pigmented ciliary epithelial cells |
| SG10201909544YA (en) * | 2019-10-11 | 2021-05-28 | Nat Univ Singapore | Genetically Modified T Cells And Uses Thereof |
| CA3158118A1 (en) * | 2019-11-13 | 2021-05-20 | Julie Carson | Methods of manufacturing car-t cells |
| US20210139850A1 (en) * | 2019-11-13 | 2021-05-13 | Crispr Therapeutics Ag | Manufacturing process for making t cells expressing chimeric antigen receptors |
| CN113122576A (zh) * | 2019-12-31 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种通用型truck-t细胞、其制备方法以及用途 |
| WO2021137241A1 (en) * | 2020-01-02 | 2021-07-08 | Edity Therapeutics Ltd. | Delivery compositions and methods |
| EP4110356A4 (en) * | 2020-02-28 | 2024-03-27 | Wisconsin Alumni Research Foundation | NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING |
| WO2021189059A2 (en) * | 2020-03-20 | 2021-09-23 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
| EP4172213A1 (en) * | 2020-06-29 | 2023-05-03 | Cell Medica Inc. | Methods and compositions for the reduction of chimeric antigen receptor tonic signaling |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| WO2022023576A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
| CA3188431A1 (en) * | 2020-08-07 | 2022-02-10 | Carsten LINNEMANN | Methods to enrich genetically engineered t cells |
| WO2022072712A1 (en) * | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Chimeric antigen receptor expression systems |
| AU2021392094A1 (en) * | 2020-12-01 | 2023-07-06 | Lepton Pharmaceuticals Ltd. | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| MX2023006395A (es) | 2020-12-03 | 2023-06-15 | Century Therapeutics Inc | Celulas dise?adas geneticamente y usos de estas. |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4019538A1 (en) | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes |
| US20250041412A1 (en) | 2021-03-11 | 2025-02-06 | Institut Curie | Transmembrane neoantigenic peptides |
| JP2024510981A (ja) | 2021-03-11 | 2024-03-12 | ムネモ・セラピューティクス | 腫瘍ネオ抗原ペプチド及びその使用 |
| CA3212964A1 (en) | 2021-03-11 | 2022-09-15 | Mnemo Therapeutics | Tumor neoantigenic peptides |
| JP2024517968A (ja) * | 2021-05-14 | 2024-04-23 | アピア バイオ， インコーポレイテッド | 幹細胞からの操作されたｔ細胞の産生 |
| EP4413031A1 (en) | 2021-10-06 | 2024-08-14 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| CN118871572A (zh) * | 2021-10-14 | 2024-10-29 | 阿彼雅生物有限公司 | 使用多种t细胞受体对干细胞t细胞进行工程化 |
| AU2022366987A1 (en) | 2021-10-14 | 2024-05-16 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| WO2023091783A1 (en) * | 2021-11-22 | 2023-05-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineered immune cells with reduced sirt6 expression |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| CN120077132A (zh) | 2022-01-21 | 2025-05-30 | 姆内莫治疗公司 | Rna对suv39h1表达的调控 |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| WO2023178227A2 (en) * | 2022-03-17 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Chimeric lactate receptor engineered t cells |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024039576A2 (en) | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| WO2024050551A2 (en) * | 2022-09-02 | 2024-03-07 | Oncosenx, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
| BE1031219B1 (fr) | 2022-12-28 | 2024-07-29 | Quidditas Sa | Composition, cellules immunitaires la comprenant et utilisation de ces dernières |
| WO2025096594A2 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| WO2025096560A1 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025213167A1 (en) * | 2024-04-05 | 2025-10-09 | Roswell Park Cancer Institute Corporation | Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002059263A2 (en) | 2000-12-19 | 2002-08-01 | Sunol Molecular Corporation | Transgenic animals comprising a humanized immune system |
| ATE279441T1 (de) | 2001-12-22 | 2004-10-15 | 4Antibody Ag | Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen |
| CA2471392A1 (en) | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005026718A1 (en) | 2003-08-28 | 2005-03-24 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| JP5271901B2 (ja) | 2007-06-11 | 2013-08-21 | タカラバイオ株式会社 | 特異的遺伝子発現方法 |
| ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| KR20120097483A (ko) * | 2009-07-24 | 2012-09-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 게놈 편집을 위한 방법 |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| PT2496698T (pt) | 2009-11-03 | 2019-04-18 | Hope City | Recetor de fator de crescimento epidermal truncado (egfrt) para seleção de células t transduzidas |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2596011B1 (en) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
| WO2013026833A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| DK2839013T3 (da) | 2012-04-18 | 2020-09-14 | Univ Leland Stanford Junior | Ikke-disruptiv-gen-targetering |
| US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| JP6401704B2 (ja) * | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス， インコーポレイテッド | Ｔ細胞を修飾する化合物およびその使用 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| SI3613439T1 (sl) | 2013-02-15 | 2021-11-30 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njegove uporabe |
| US9499855B2 (en) * | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| EP2975942B1 (en) | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| JP6578271B2 (ja) | 2013-04-17 | 2019-09-18 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫抑制ＴＧＦ−βシグナルコンバーター |
| CN112795594B (zh) | 2013-05-14 | 2025-09-19 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| AU2015233347A1 (en) | 2014-03-21 | 2016-09-08 | Cellectis | Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS) |
| US20170044500A1 (en) | 2014-04-24 | 2017-02-16 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| CA2948614A1 (en) | 2014-05-09 | 2015-11-12 | Research Foundation Of The City University Of New York | Tcr(alpha)-lcr-derived gene regulatory cassettes |
| WO2015188065A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
| SG11201609634YA (en) | 2014-06-06 | 2016-12-29 | Regeneron Pharma | Methods and compositions for modifying a targeted locus |
| MX2017003640A (es) | 2014-09-19 | 2017-10-31 | Regeneron Pharma | Receptores antigenicos quimericos. |
| US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| MX2017012407A (es) | 2015-03-27 | 2018-03-07 | Harvard College | Celulas t modificadas y métodos para hacer y usar las mismas. |
| WO2016166268A1 (en) | 2015-04-17 | 2016-10-20 | Cellectis | Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes |
| CN207773375U (zh) * | 2015-05-15 | 2018-08-28 | 奥罗皮艇有限公司 | 可折叠船只 |
| WO2017011519A1 (en) * | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| CA2993431A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Nuclease based knockouts of immunological checkpoint genes in immune cells |
| CN108601821B (zh) * | 2015-10-05 | 2023-09-19 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| ES2883116T3 (es) * | 2015-10-05 | 2021-12-07 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| JP7534070B2 (ja) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| EP3377523A4 (en) | 2015-11-19 | 2019-06-19 | The Regents of The University of California | CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF |
| US20190241910A1 (en) | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| CU24649B1 (es) | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| JP2019510503A (ja) | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| AU2017250769B2 (en) | 2016-04-15 | 2022-07-14 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
-
2017
- 2017-04-14 AU AU2017250769A patent/AU2017250769B2/en active Active
- 2017-04-14 ES ES17735670T patent/ES2933961T3/es active Active
- 2017-04-14 CN CN201780037351.1A patent/CN109790517B/zh active Active
- 2017-04-14 KR KR1020237042980A patent/KR20240000616A/ko active Pending
- 2017-04-14 PT PT177356706T patent/PT3443075T/pt unknown
- 2017-04-14 US US16/091,494 patent/US11377637B2/en active Active
- 2017-04-14 BR BR112018071199-3A patent/BR112018071199A2/pt active Search and Examination
- 2017-04-14 EP EP25181439.8A patent/EP4628587A2/en active Pending
- 2017-04-14 SG SG11201808831TA patent/SG11201808831TA/en unknown
- 2017-04-14 KR KR1020227029151A patent/KR102614675B1/ko active Active
- 2017-04-14 WO PCT/US2017/027601 patent/WO2017180989A2/en not_active Ceased
- 2017-04-14 EP EP17735670.6A patent/EP3443075B1/en active Active
- 2017-04-14 KR KR1020187032919A patent/KR102437015B1/ko active Active
- 2017-04-14 JP JP2018554069A patent/JP7058223B2/ja active Active
- 2017-04-14 ES ES22197444T patent/ES3039670T3/es active Active
- 2017-04-14 EP EP22197444.7A patent/EP4180519B1/en active Active
- 2017-04-14 PT PT221974447T patent/PT4180519T/pt unknown
-
2022
- 2022-05-25 US US17/824,650 patent/US12404316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511236A5 (enExample) | ||
| KR102691932B1 (ko) | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 | |
| US11981721B2 (en) | Transposon-based transfection system for primary cells | |
| KR102495308B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| JP7005346B2 (ja) | 養子細胞免疫療法の有効性を増強させるための組成物および方法 | |
| JP6161098B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Gowrishankar et al. | Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells | |
| IL274179B1 (en) | Targeted replacement of endogenous T cell receptors | |
| JP2022164858A (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| KR20200015939A (ko) | 신규의 세포 태그의 발현 | |
| CN109415687A (zh) | 嵌合抗原受体t细胞组合物 | |
| KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
| CN110462040A (zh) | 通过新基因开关表达系统调节多肽的表达 | |
| CA2978171A1 (en) | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof | |
| CN106535925A (zh) | 基于car的免疫治疗 | |
| JP2021518747A (ja) | Ｒｎａ不安定化エレメントを使用した遺伝子発現の調整 | |
| Middelburg et al. | The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent | |
| Reuter et al. | Immunostimulation by OX40 ligand transgenic Ewing sarcoma cells | |
| JP6723164B2 (ja) | Ｔ細胞集団の改変方法 | |
| US11098283B2 (en) | T cells modified to overexpress c-Myb | |
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| KR20200129959A (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| WO2010114129A1 (ja) | Ｔ細胞レセプター及び該レセプターをコードする核酸 | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| Yang et al. | Analysis of the complex genomic structure of Bcl-x and its relationship to Bcl-xγ expression after CD28-dependent costimulation |